Home
Research
Submit Article
News
Sectors
Advertise
Premium
i On The Market - Daily Newsletter
Every trading day, be ready to attack the market instead of reacting to the market.
You will know where the key technical resistance and support levels are and what the market is likely to do next. iStock will arm you with a target list of stocks to buy and sell - right now - based on our exclusive, proprietary trading models.
Two Week FREE Trial
About Us
About Us
Editorial Staff
Terms and Conditions
Privacy Policy
Contact Us
Enter Symbol
Company
Overview
Research Notes
Company Profile
Competitors
Community
Stock Sentiment
Whisper Estimates
Enter Estimates
Analysis
Blog Articles
Press Releases
Charts
Technical Charts
Analyst
Analyst Ratings
Analyst Estimates
Sales Estimates
Ratios
Financial Ratios
Technicals
Press Releases
PROLOR Biotech Initiates Pivotal Phase III Trial Of Its Longer-Acting Version Of Human Growth Hormone
OPKO Surpasses 50% Enrollment in First Phase 3 Trial of RayaldyTM (CTAP101 Capsules)
OPKO Announces First Quarter 2013 Operating and Financial Highlights
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of Claims of Breaches of Fiduciary Duty by the Board of PROLOR Biotech, Inc. in Connection With the Sale of the Company to OPKO Health, Inc.
Acquisition of PROLOR Biotech, Inc. by OPKO Health, Inc. May Not Be in the Best Interests of PROLOR Shareholders
Management Buyout Of PROLOR - Law Firm Seeks Higher Price For Shareholders
OPKO Health To Acquire PROLOR Biotech
OPKO Health Acquires Interest in Growing Russian Pharmaceutical Company
OPKO Health Announces Publication of Study Detecting Antibodies in NMO Patients Using OPKO Screening Technology
Prescription for Success: Commercialization Efforts, Acquisitions and Enhanced Patent Protection - Research Report on PAREXEL International, Ironwood Pharmaceuticals, Opko Health, Amarin Corporation, Progenics Pharmaceuticals
Pre-Market Analysis on MGIC Investment, Ultra Petroleum, Opko Health, and Accuray
RXi Pharmaceuticals and OPKO Health Announce Strategic Pooling of RNAi Assets
OPKO Health Completes Acquisition of Two Phase 3 Products
OPKO Point-of-Care Technology Demonstrated on Mobile Device with Cloud Connectivity to Diagnose and Track Disease in Africa
OPKO Health Completes Acquisition of Brazilian Pharmaceutical Company
Should Recent Insider Buying on YUM, OPK, ASBC and TDG Matter to You?
Clarification Regarding Exercise and Sale of Common Stock Options by OPKO Health Company Officer
OPKO Closes Offering of $175 Million of 3.00% Convertible Senior Notes Due 2033
OPKO Prices Offering of $175 Million of 3.00% Convertible Senior Notes Due 2033
OPKO Announces Proposed Private Offering of $150 Million Convertible Senior Notes Due 2033
OPKO Health Expands Collaboration with Bristol-Myers Squibb
OPKO Health to Acquire Two Phase 3 Products
OPKO Health to Present at the 31st Annual J.P. Morgan Healthcare Conference
Should Recent Insider Buying on GS, PFG, OPK and GPC Matter to You?
OPKO Health to Expand Latin American Presence with Acquisition of Brazilian Pharmaceutical Company
OPKO Health Completes Acquisition of CLIA Laboratory
Should Recent Insider Buying on AGNC, RF, OPK and AKRX Matter to You?
OPKO Health Announces Research Grants from Mexican Technology and Science Council
OPKO Health Announces Grant to Develop Tuberculosis Diagnostics Technology
OPKO Health to Acquire Prost-Data (OURLab), a Profitable CLIA Laboratory with Strong U.S. Presence in Urologic Pathology
OPKO Health Announces Launch of 4Kscore(tm) in Europe
OPKO Health Announces Acquisition of Growing European Healthcare Company
OPKO Health Announces Appointment of Juan F. Rodriguez as Chief Financial Officer
Today's Market Driven by Key Factors - Featured Research on Alexion Pharmaceuticals, Inc. and Opko Health Inc.
OPKO Health To Acquire Stake in Israeli Hepatitis B Vaccine Manufacturer
OPKO Health to Present at the Jefferies 2012 Global Healthcare Conference
OPKO Health Receives Core Technology U.S. Patent Allowance
OPKO Health Receives Important U.S. Patent Allowance
OPKO Health Enters into License Agreement with International Health Technology for Next Generation Prostate Cancer Biomarker Panel
OPKO Health Receives Important U.S. Patent Allowance
OPKO Health Announces the Start of Phase 3 Clinical Trials of Rolapitant for the Prevention of CINV
OPKO Health Acquires Chilean Pharmaceutical Company
OPKO Health Announces License Agreement for OPKO's Alzheimer's Diagnostic Technology
OPKO Health Expands Collaboration with Arctic Partners
OPKO Health and The Scripps Research Institute Announce Global License Agreement for a Novel Compound That Blocks Brain Cell Destruction in Parkinson's Disease
More Regulation Looms for the Medical Equipment and Supplies Industry
OPKO Invests in BioZone Pharmaceuticals, Inc.
2012 Economic Outlook - Report Highlights Ariad Pharmaceuticals, Inc. and Opko Health Inc.
OPKO Health, Inc. Invests in ChromaDex? Corp.
OPKO Health Announces Commencement of U.S. Clinical Trial for Point-of-Care Prostate Specific Antigen Test
OPKO Health to Present at the Lazard Capital Markets 8th Annual Healthcare Conference
OPKO Health Subsidiary Receives Wall Street Journal 2011 Technology Innovation Award
OPKO Health to Share in NIH Grant Award
OPKO Health Announces Acquisition of Claros Diagnostics
OPKO Announces Investment by Teva in Cocrystal Discovery Inc.
OPKO Health to Transfer Listing of Common Stock to the New York Stock Exchange
OPKO Health Announces Grant from Penn Center for Orphan Disease Research and Therapy
OPKO Invests in Cardiac Device Company
OPKO Health Repurchases Approximately 2.4 Million Shares
OPKO Health Announces Research Grants from Mexican Technology and Science Council
OPKO Health Announces Redemption of Series A Preferred Stock
OPKO Health to Present at the Jefferies 2011 Global Healthcare Conference
OPKO Health Announces Grant from Dravet Syndrome Foundation
OPKO Health Announces Completion of Public Offering of Common Stock
OPKO Health Announces Pricing of Public Offering of Common Stock
OPKO Health Acquires Biotechnology Company with Unique Platform Technology to Develop New Drugs
OPKO Health to Collaborate with Bristol-Myers Squibb on Blood Test for Alzheimer's Disease
OPKO Health Announces Publication on Technology Underlying Blood Test for Alzheimer's Disease
OPKO Health to Present at the 29th Annual J.P. Morgan Healthcare Conference
Fundamental data is provided by
Zacks Investment Research
, and Commentary, news and Press Releases provided by YellowBrix and
Quotemedia
. Advertisement partners
Investing Channel
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.
{1}
##LOC[OK]##
{1}
##LOC[OK]##
##LOC[Cancel]##
{1}
##LOC[OK]##
##LOC[Cancel]##